2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
10
Leukemia, Myeloid, Acute
6
Myelodysplastic Syndromes
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Lymphoma, T-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cytarabine
72
Etoposide
29
Daunorubicin
25
Filgrastim
24
Idarubicin
22
Mitoxantrone
21
Busulfan
21
Peripheral Blood Stem Cell Transplantation
20
Cyclophosphamide
20
fludarabine phosphate
18
Gemtuzumab
13
Antilymphocyte Serum
12
tipifarnib
11
Radiotherapy
11
Gene Expression Profiling
10
Flow Cytometry
10
Cyclosporine
10
Clofarabine
10
sargramostim
9
Methotrexate
9
Azacitidine
8
aldesleukin
6
Vorinostat
6
Topotecan
6
Tacrolimus
6
valspodar
5
alvocidib
5
Whole-Body Irradiation
5
Granulocyte Colony-Stimulating Factor
5
Cord Blood Stem Cell Transplantation
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Megakaryoblastic, Acute
×
BI 6727
×
Clear all
NCT02527174
2017-04-05
VIAC
University of Alberta
Phase 1
Withdrawn